Clinical trials: Hidradenitis Suppurativa
Hidradenitis Suppurativa
Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
Currently, there is limited evidence showing increased resolution of HS flares with higher doses of intralesional triamcinolone (ILTAC) as well as a difference in side effect profile between the doses.
- Trial name
- NCT04582669
- Testing
- Intralesional Triamcinolone 10 mg/mL, Intralesional Triamcinolone 20 mg/mL, Intralesional Triamcinolone 40 mg/mL
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Hidradenitis Suppurativa
A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.
Purpose: To evaluate the effectiveness of intralesional triamcinolone for the treatment of hidradenitis suppurativa (HS) Participants: Patients diagnosed with Hidradenitis Suppurativa that have active inflammatory HS lesions.
- Trial name
- NCT02781818
- Testing
- Triamcinolone Acetonide 10mg/mL, Triamcinolone Acetonide 40mg/mL, Normal Saline
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill